United States Epigenetics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents and Kits, Antibodies, ChiP-seq Kits, Bisulfite Conversion Kits, Whole Genome Amplification Kits, RNA Sequencing Kits, Others), By Technology (NDNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification, Others), By Application (Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Others), By End Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies) and Forecasts, 2026-2034

United States Epigenetics Market Size

The United States Epigenetics Market size was valued at USD 5.12 billion in 2025 and is projected to grow from USD 5.63 billion in 2026 to reach USD 11.99 billion by 2034, growing at a CAGR of 9.92% during the forecast period 2026–2034.

The rising cases of chronic diseases like CVDs, cancer, neurodegenerative conditions, etc, primarily drive the United States epigenetics market. The burden of these chronic diseases further increases with a surge in the aging population, subsequently boosting the US epigenetics market. Moreover, the regional market players are collaborating with each other to enhance their market share, thereby creating opportunities for market growth.

Product Insights

The reagents and kits segment dominates the global epigenetics market and is projected to exhibit a CAGR of 16.3% over the forecast period. The reagents and kits segment encompasses essential tools for epigenetic research, including DNA methylation kits, chromatin immunoprecipitation (ChIP) kits, and histone modification antibodies. These products facilitate accurate and efficient analysis of epigenetic modifications, driving advancements in both basic research and clinical applications.

Request Customizationto receive a tailored report.

Application Insights

The oncology segment is estimated to own the highest market share and grow at a CAGR of 16.1% over the forecast period. The oncology segment leverages epigenetic insights to develop novel cancer diagnostics and therapeutics. Epigenetic modifications like DNA methylation and histone modification are crucial in cancer development, making them targets for innovative treatments and biomarkers for early cancer detection, prognosis, and personalized medicine.

End-Users Insights

The pharmaceutical and biotechnology companies contributed to the largest market share and is anticipated to exhibit at a CAGR of 16.5% over the forecast period. Pharmaceutical and biotechnology companies are key players in the epigenetics market, focusing on the development of epigenetic drugs and therapies. These companies invest heavily in R&D to discover new epigenetic targets and create therapies for diseases such as cancer, neurological disorders, and autoimmune diseases.

Speak to an Analystto discuss market opportunities.

Country Insights

The US epigenetics market is being driven by factors like extensive R&D activities, the presence of key market players, and supportive regulatory frameworks. In the US, the flourishing prevalence of chronic diseases, robust healthcare infrastructure, and favorable reimbursement policies drive the adoption of epigenetic technologies. Moreover, the rising aging population is further accelerating the US epigenetics market.

• For instance, projections indicate that the number of Americans aged 65 and older will surpass 95 million by 2060, a significant increase from the 52 million reported in 2018. Moreover, there has also been a rise in investment in the firms involved in the development of epigenetics therapeutics.
• For instance, in January 2024, Moonwalk Biosciences, a genomic medicine company that is at the forefront of precision epigenetic medications in San Fransisco, announced the successful completion of USD 57 million in seed and Series A financing. The financing will facilitate the ongoing development of Moonwalk's epigenetic profiling and engineering technology platform, as well as the advancement of its pipeline of epigenetic therapeutics toward the clinic. Moonwalk's objective is to reprogram cells to their healthy state by targeting the epigenetic code, the genome software. This profoundly enables a new approach to the discovery and development of therapies. Thus, the above factors are anticipated to boost the United States epigenetics market growth.

List of Key and Emerging Players in United States Epigenetics Market